Get the Stockscreener App
0.99
7.48%
-0.08
Coherus Oncology Inc stock is traded at $0.99, with a volume of 938.49K.
It is down -7.48% in the last 24 hours and down -18.85% over the past month.
Coherus Oncology Inc is a fully integrated commercial-stage inventive oncology company with an approved next-generation PD-1 inhibitor, LOQTORZI, and a pipeline that includes two mid-stage clinical candidates targeting liver, lung, head & neck, and other cancers. Its portfolio includes LOQTORZI which was developed for its ability to block PD-1 interactions with its ligands, PD-L1 and PD-L2, by binding to the FG loop on the PD-1 receptor. Company believe blocking PD-1 interactions with PD-L1 and PD-L2 can help to promote the immune systems.
See More
Previous Close:
$1.07
Open:
$1.07
24h Volume:
938.49K
Relative Volume:
0.56
Market Cap:
$152.96M
Revenue:
$46.88M
Net Income/Loss:
$-172.66M
P/E Ratio:
-0.7945
EPS:
-1.2461
Net Cash Flow:
$-170.57M
1W Performance:
-7.48%
1M Performance:
-18.85%
6M Performance:
-47.89%
1Y Performance:
-42.11%
1-Day Range:
$0.9868
$1.07
1-Week Range:
$0.9868
$1.09
52-Week Range:
$0.974
$2.6158
Coherus Oncology Inc Stock (CHRS) Company Profile
Name
Coherus Oncology Inc
Sector
Industry
Phone
(650) 649-3530
Address
C/O DENNIS M. LANFEAR, REDWOOD CITY, CA
Compare CHRS vs VRTX, MRNA, REGN, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CHRS
Coherus Oncology Inc
|
0.99 | 152.96M | 46.88M | -172.66M | -170.57M | -1.2461 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Coherus Oncology Inc Stock (CHRS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-11-26 | Initiated | Guggenheim | Buy |
| Jan-23-26 | Initiated | Oppenheimer | Outperform |
| Sep-04-25 | Upgrade | Maxim Group | Hold → Buy |
| Aug-16-24 | Downgrade | UBS | Buy → Neutral |
| Nov-17-23 | Initiated | Robert W. Baird | Outperform |
| Nov-08-23 | Downgrade | Maxim Group | Buy → Hold |
| Jul-24-23 | Initiated | Citigroup | Buy |
| May-01-23 | Initiated | Truist | Buy |
| Mar-28-23 | Upgrade | UBS | Neutral → Buy |
| Jun-14-22 | Initiated | UBS | Neutral |
| Mar-07-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-16-20 | Initiated | BofA Securities | Neutral |
| Apr-17-20 | Initiated | SunTrust | Buy |
| Aug-13-19 | Initiated | Mizuho | Buy |
| Aug-02-19 | Reiterated | H.C. Wainwright | Buy |
| Aug-02-19 | Reiterated | Maxim Group | Buy |
| Jun-11-19 | Initiated | Barclays | Overweight |
| May-07-19 | Initiated | H.C. Wainwright | Buy |
| Aug-28-18 | Initiated | H.C. Wainwright | Buy |
| Mar-09-18 | Reiterated | Maxim Group | Buy |
| Aug-08-17 | Reiterated | JP Morgan | Overweight |
| Jun-13-17 | Reiterated | Maxim Group | Buy |
| May-05-17 | Initiated | BMO Capital Markets | Outperform |
| Oct-19-16 | Initiated | Robert W. Baird | Outperform |
| Sep-07-16 | Initiated | Maxim Group | Buy |
| Jul-27-16 | Initiated | Citigroup | Buy |
| Jan-20-16 | Initiated | Credit Suisse | Outperform |
View All
Coherus Oncology Inc Stock (CHRS) Latest News
Coherus Oncology Initiates Process to Sell Remaining Legacy Biosimilars Assets, Announces CVR Details - Quiver Quantitative
Eligible shareholders may share proceeds from Coherus' assets tied to similar medicines. The sale process has begun. - stocktitan.net
Coherus Oncology Starts Process to Sell Remaining Biosimilar Assets - Yahoo Finance
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets - Yahoo Finance
Coherus Oncology Initiates Process to Sell Remaining Legacy Biosimilars Assets, Announces CVR Details - Quiver Quantitative
Coherus Oncology Retains Oppenheimer & Co. to Market Legacy BioSimilar Assets - The Manila Times
Coherus BioSciences stock reacts to BlackRock stake and latest oncology focus - ad-hoc-news.de
CHRS Q2 2026 Earnings: Narrower-than-Expected Loss Drives 2.59% Share GainPost-Earnings Reaction - vinanet.vn
Coherus to Participate in Upcoming Investor Conferences - Yahoo Finance
Coherus Oncology files $50M at-the-market sales agreement with Leerink Partners - TradingView
Coherus (CHRS) Quarter in Focus: The Bottom-Line Figure Beats Its Comparison at the Close; Closing Reaction: Shares Finish 4.23% Down for the Current SessionEarnings Growth Analysis - vinanet.vn
Coherus: 'Hold' On Several Tagmokitug 2026 Catalysts And Casdozokitug HCC Drug Development - Seeking Alpha
Coherus (CHRS) Q2 2026 Results: Reported EPS Tops Expectations in Latest Trading; Market Reaction: Shares Finish 16.52% UpEarnings Power Value - vinanet.vn
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com India
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com South Africa
CHRS Looks 10.6% Overvalued on GF Value™ - GuruFocus
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com Nigeria
Coherus Oncology Secures $55M Term Loan, Extends Debt Maturity to 2031 - Minichart
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com Canada
Form 8K Coherus BioSciences Inc For: 17 August By Investing.com - Investing.com UK
Coherus Declares Special Dividend of Biosimilar Contingent Value Rights, Payable Oct. 7 to Holders of Record Sept. 30 - marketscreener.com
Coherus Oncology Announces Special Dividend Of Biosimilar Contingent Value Rights - tradingview.com
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire
Coherus will give eligible holders rights to cash from former assets—but they may expire unpaid - Stock Titan
Coherus Oncology, Inc., Coherus Intermediate Corp, Surface Oncology, LLC, and InteKrin Therapeutics Inc., Enter into Loan and Security Agreement - marketscreener.com
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - Yahoo Finance
Coherus Oncology Announces Special Dividend of Biosimilar Contingent Value Rights - GlobeNewswire
Coherus Oncology Announces Special Dividend of Contingent Value Rights Tied to Legacy Biosimilar Asset Sales - Quiver Quantitative
Q3 EPS Estimates for Coherus Oncology Cut by HC Wainwright - MarketBeat
Coherus Oncology (CHRS) Q2 2026 Earnings Call Transcript - The Globe and Mail
ETFs Investing in Coherus Oncology, Inc. Stocks - TradingView
CHRS Maintained by Guggenheim -- Price Target Lowered to $10.00 - GuruFocus
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Nigeria
Coherus Oncology Is Maintained at Buy by Guggenheim - Moomoo
H.C. Wainwright Maintains Coherus Oncology(CHRS.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Coherus Oncology, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Post-Earnings Moves - dars.gov.et
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27High Conviction Picks - dars.gov.et
Coherus Oncology (CHRS) Drops 7.24% to $1.34, Pressing Key Support at $1.27Algorithmic Stock Picks - dars.gov.et
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: - GuruFocus
Coherus Oncology Inc (CHRS) (Q2 2026) Earnings Call Highlights: LOQTORZI Growth and Pipeline ... - finance.yahoo.com
Coherus Oncology, Inc. 2026 Q2 10-Q Highlights: Financials, Risks, and Forward-Looking Statements for Investors - Minichart
Coherus Oncology Q2 2026 Results: LOQTORZI Revenue Growth, Pipeline Progress, and Financial Update - Minichart
CHRS Looks 83.5% Overvalued on GF Value™ - GuruFocus
Coherus Oncology Q2 Earnings Call Highlights - MarketBeat
Coherus Oncology : Reports Second Quarter 2026 Financial Results and Provides Business Update - marketscreener.com
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com Canada
Earnings call transcript: Coherus Oncology posts Q2 2026 EPS beat, shares fall - Investing.com
Coherus Oncology (NASDAQ:CHRS) Announces Quarterly Earnings Results - MarketBeat
Coherus Oncology Inc Stock (CHRS) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.22%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):